President Trump got 16 of America's largest pharmaceutical companies to the table. He applied real pressure, extracted public commitments on drug pricing that no previous administration had managed to get, and announced the deals from the White House. It should have been a historic win for American patients.

Then the SEC filings came out.

In this replay of Episode 6, Rob Burgess walks through what those 16 companies told their shareholders — in legally binding documents where they cannot misrepresent material fact — about what they actually agreed to. The gap between the public announcement and the private disclosure is what this episode is about.

The bottom line: This episode is not an argument against President Trump's drug pricing agenda. It's an argument for taking it further. The president started something real. The SEC filings show exactly how Big Pharma is planning to escape it. The answer is codification — permanent, enforceable, comprehensive law that doesn't expire in three years.

🔔 New episodes every week — subscribe so you don't miss one. 🌐 Get involved at BustBigPharma.com

Big Pharma has one argument they wheel out every single time anyone tries to hold them accountable. Touch our prices and you'll kill innovation. It sounds compelling. It's made legislators flinch for decades. It's made ordinary Americans hesitate. And in this Replay of Episode 5 of Bust Big Pharma, Rob Burgess runs it through the data — study by study, number by number, company by company.

The results are not what the industry would like you to see.

This episode is the most research-dense of the series so far. Rob pulls from peer-reviewed studies in the British Medical Journal and the Journal of the American Medical Association, a decade of FDA approval data, and the industry's own audited financial filings to build a case that the innovation argument isn't a fact. It's a defense. And it doesn't hold up.

The bottom line: This is not an innovation system. It's a pricing system with an innovation story attached to it. The data says so. Their own books say so. And the American people deserve to know.

🔔 New episodes every week — subscribe so you don't miss one.

🌐 Get involved at BustBigPharma.com

#BustBigPharma #DrugPricing #PharmaceuticalIndustry #BigPharma #PharmaReform #MAHA #MakeAmericaHealthyAgain #DrugPriceReform #Innovation #RFKJr #Humira #OrphanDrugs #PrescriptionDrugPrices #AmericansForPharmaReform

In 2025, AbbVie cut its research and development budget by 29% — the steepest R&D cut of any major pharmaceutical company that year. In the same year, AbbVie's CEO received a 75% pay raise, bringing his total compensation to $32.5 million. Same company. Same year. Same pool of capital. That's where this replay of Episode 9 starts. And it only gets more specific from there.

Rob Burgess follows the money through the full 2025 financial picture for the 16 largest pharmaceutical companies — the advertising budgets, the executive compensation structures, the shareholder returns, the R&D cuts, and the 22,000 jobs eliminated — and then audits the decade of leadership at PhRMA, the industry's most powerful lobbying organization, that produced these numbers. Every argument the industry makes in defense of its behavior gets examined against the data. None of them hold.

🔔 New episodes every week — subscribe so you don't miss one.
🌐 Get involved at BustBigPharma.com
#DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch


Chapters:
00:00 — AbbVie: The Clearest Example
02:18 — Follow the Money: Where $177 Billion Went
05:23 — The $9 Billion Ad Machine
11:12 — Trump's Crackdown on Misleading Ads
15:19 — The R&D Cuts, By Company
18:12 — Why CEO Pay Is Designed to Raise Prices
22:46 — A Decade of PhRMA Leadership, Audited
31:22 — The Industry's Arguments, Answered
35:44 — Three Reforms That Would Fix the Incentives

The FDA is supposed to be your watchdog. The agency that stands between you and an industry that, left unchecked, will prioritize profits over your safety. So what happens when the watchdog goes to work for the industry it was supposed to be watching?

In this replay of Episode 4, Rob Burgess names names. Three of them. Patrizia Cavazzoni ran the FDA's drug approval center for years — then left for Pfizer as Chief Medical Officer. Peter Marks spent nine years as the FDA's top vaccine regulator — then landed at Eli Lilly as Senior Vice President. Scott Gottlieb ran the entire FDA — then joined Pfizer's board of directors within months of leaving. Rob breaks down what each of them knew, what that knowledge is worth, and why the current law allows all of it.

The bottom line: The people running America's drug approval process are one year away from going to work for the companies that want drugs to be expensive. That's not America First. That's industry first.

🔔 New episodes every week — subscribe so you don't miss one.
🌐 Get involved at BustBigPharma.com

00:00 — Introducing the Revolving Door
03:40 — What the FDA Is Supposed to Be
06:07 — Patrizia Cavazzoni: From FDA Drug Chief to Pfizer CMO
11:25 — Peter Marks: From FDA Vaccine Chief to Eli Lilly
16:28 — Scott Gottlieb: The Blueprint
19:34 — The System, Not the Individuals
23:50 — Why the Revolving Door Is an Issue for Everyone
27:23 — What Real Reform Looks Like

One drug. One molecule. 154 patents. That's not a typo — and in this replay episode of Bust Big Pharma, Rob Burgess explains exactly what it means for your pharmacy bill.

Ozempic is the most talked-about drug in America right now. But behind the celebrity endorsements and the glossy TV ads is a story most people never hear: how Novo Nordisk built a legal fortress around a single molecule to keep cheaper competition off the market for years — and how much that delay is worth to them. The answer is $166 billion. Rob breaks down the patent thicketing playbook, why the GLP-1 market changes everything, and how Most Favored Nation pricing is the policy that Big Pharma is actually scared of.

The bottom line: This isn't just an Ozempic story. It's a playbook. And once you see how it works, you start seeing it everywhere.

🔔 New episodes every week — subscribe so you don't miss one.

🌐 Get involved at BustBigPharma.com

The Bust Big Pharma bus tour has now crossed more than 30 states, done hundreds of events, and collected enough petition signatures and engagement data to identify exactly which Senate races Big Pharma is most vulnerable in. The man who ran the ground operation for the 2025 tour knows exactly what that looked like from the inside.

In Episode 12, Rob sits down with Corey Stevens — former National Field Director for Americans for Pharma Reform — to talk about what happens when you take this issue directly to the American people. Town halls in rural New Mexico. 180 people showing up in a Texas border town. An elderly couple in Michigan asking for a bucket of stress ball remotes because they're fed up with pharma ads on their TV. Corey breaks down what he saw on the ground, what it told him about the 2026 map, and what he's telling his candidates right now.

The bottom line: Big Pharma has $450 million in lobbying. AFPR has a bus, a petition, and a growing list of voters who are fed up. Corey Stevens spent 2025 crossing the country collecting proof that the second thing is more powerful than the first.

🔔 New episodes every week — subscribe so you don't miss one. 🌐 Get involved at BustBigPharma.com

#DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch

Chapters:
00:00 — Meet the Man Who Ran the Bus Tour
02:10 — What 200 People Who Agree on Nothing Have in Common
05:19 — How Louisiana Became a Red Flag
07:26 — Texas, Paxton, and the Pattern
09:08 — Voter Currency vs. Political Capital
13:51 — What Down-Ballot Candidates Should Be Saying
17:35 — How Pharma Ads Are Targeting the Next Generation
20:07 — The Michigan Moment

Last week, Ken Paxton won the Republican Senate primary runoff in Texas. He beat John Cornyn — six-term incumbent, former Senate majority whip, the establishment's choice — because Texas Republican primary voters chose the candidate who had sued Big Pharma. Multiple times. Using words like "illegal" and "bribe."

In Episode 11, Rob Burgess connects those results to four other Senate races unfolding right now — and shows you exactly what to do with the information.

Texas. Ohio. Georgia. Colorado. New Jersey. In every one of these races, pharmaceutical accountability has emerged as a defining issue. Rob examines each one honestly — the legislative records, the contribution histories, the rhetorical commitments versus the documented actions — and closes with three specific questions every voter should be asking their Senate candidates before November.

The bottom line: The pharmaceutical industry cannot lobby every voter. It can lobby every senator. Your job is to create senators the lobby cannot own.

🔔 New episodes every week — subscribe so you don't miss one.
🌐 Get involved at BustBigPharma.com

#DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch

00:00 — Ken Paxton Just Beat the Senate Establishment
02:27 — Five Races. One Issue.
04:47 — Texas: Both Candidates Are Running Against Big Pharma
08:16 — Ohio: The $1.4 Million Question
12:08 — Georgia: Ossoff Passed the Laws
15:17 — New Jersey and Colorado: The Argument Goes Everywhere
19:55 — What Big Pharma Is Doing With Its Money in 2026
25:31 — Three Questions to Ask Before You Vote

On May 16th, Bill Cassidy — Chairman of the Senate Health Committee and the top Republican recipient of pharmaceutical money in the 2024 cycle — came in third in his own Republican primary. A senator who took over $1 million from Big Pharma, blocked a fast-track MFN vote, and killed his own codification bill before it ever got a hearing was sent home by the voters of Louisiana.

In Episode 10, Rob Burgess uses that result as the opening argument — and then spends the rest of the episode dismantling every major industry argument standing between American patients and drug pricing reform.

The innovation argument. The China argument. The supply chain argument. The price controls argument. One by one, on the merits, with the data. And then: what TrumpRx actually is, what it isn't, why the industry cooperates with it, and why MFN codification is the bill they're spending $450 million a year to prevent from ever coming due.

The bottom line: The industry's math has always been about money. The reform movement's math is about votes. The votes won — in Louisiana, on a Saturday night. Every member of Congress sitting on pharmaceutical contributions should be doing the same math right now.

🔔 New episodes every week — subscribe so you don't miss one.
🌐 Get involved at BustBigPharma.com

Chapters:
00:00 — Bill Cassidy Lost. Here's Why It Matters.
04:16 — The Innovation Argument, Run Through the Data
09:11 — The Patent Bargain Big Pharma Decided Was Optional
13:09 — The China Argument Exposed
17:25 — The Supply Chain Argument, Dismantled
21:13 — MFN Pricing Is Not Socialism
25:05 — What TrumpRx Is — and What It Isn't
30:23 — The Empty Chair and What Comes Next

#DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch

Big Pharma has so much money, they don't just buy politicians — they rent both parties. That's not a conspiracy theory. That's a quote from RFK Jr., and it's exactly what Republican strategist Chris Faulkner breaks down in this episode of Bust Big Pharma.

This week's episode is a replay of a previous episode where Rob Burgess sat down with Chris — a veteran political consultant who joined the Bust Big Pharma bus tour across the Southeast — to talk about why Congress won't act on drug pricing, what the 2026 midterms mean for pharma reform, and how everyday Americans can actually move the needle, because in May of 2026, this conversation matters more than ever before.

🔔 Subscribe for new episodes every week.
🌐 Learn more at BustBigPharma.com
📧 Seen a news story pharma doesn't want covered? Email us: truth@bustbigpharma.com

0:00 — Welcome And The MFN Question
3:00 — Pharma Ads And Hidden Influence
12:40 — Taxpayer Research And Patent Loopholes
22:00 — News Conflicts And Voter Accountability
30:30 — Hollywood Turns Big Pharma Into Villains
37:40 — Affordability Politics And What Happens Next

#DrugPricing #HealthcareReform #BigPharmaExposed #PharmaGreed #CorruptionWatch